Skin depigmentation associated with toceranib phosphate in a dog.

about

Skin depigmentation associated with toceranib phosphate in a dog.

Item

http://www.wikidata.org/entity/Q53524319

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Skin depigmentation associated with toceranib phosphate in a dog.

@en

Skin depigmentation associated with toceranib phosphate in a dog.

@nl

type

Item

label

Skin depigmentation associated with toceranib phosphate in a dog.

@en

Skin depigmentation associated with toceranib phosphate in a dog.

@nl

prefLabel

Skin depigmentation associated with toceranib phosphate in a dog.

@en

Skin depigmentation associated with toceranib phosphate in a dog.

@nl

P1476

Skin depigmentation associated with toceranib phosphate in a dog.

@en

P2093

Andrea Hasbach

http://www.w3.org/2001/XMLSchema#string

Jacqueline V J Cavalcanti

http://www.w3.org/2001/XMLSchema#string

Jon Patterson

http://www.w3.org/2001/XMLSchema#string

Katie Barnes

http://www.w3.org/2001/XMLSchema#string

Paulo Vilar Saavedra

http://www.w3.org/2001/XMLSchema#string

Rahul B Dange

http://www.w3.org/2001/XMLSchema#string

P2860

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

A method for estimating the probability of adverse drug reactions

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment.

Immune-mediated adverse drug reactions.

Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.

Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.

P304

400-e95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VDE.12422

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28164401

http://www.w3.org/2001/XMLSchema#string